A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer

Young Min Park, Ki Chang Keum, Hye Ryun Kim, ByoungChul Cho, Da Hee Kim, Namhoon Cho, Se Heon Kim

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: We conducted a prospective clinical trial of combination neoadjuvant chemotherapy, transoral robotic surgery (TORS), and customized adjuvant therapy in patients with locally advanced laryngo-hypopharyngeal cancer. Methods: Between September 2008 and August 2016, 35 patients were enrolled in this clinical trial. Results: Twenty patients had hypopharyngeal cancer and 15 had laryngeal cancer. Twenty-nine patients (82.9%) had T3 disease and six patients (17.1%) had T4 disease, while 12 patients (34.3%) had stage III disease and 23 patients (65.7%) had stage IV disease. The 3-year disease-specific survival rate was 82.4% and the 3-year disease-free survival rate was 69.48%. Decannulation was successful in 31 of 34 patients at an average of 18 days postoperatively. Among all patients, 83% exhibited a favorable subjective swallowing status, while five patients (14.4%) became dependent on feeding tubes. Conclusions: Neoadjuvant chemotherapy combined with TORS and customized adjuvant therapy, based on detailed pathological information, afforded favorable oncological outcomes and preserved organ functionalities in T3–T4 laryngo-hypopharyngeal cancer.

Original languageEnglish
Pages (from-to)864-871
Number of pages8
JournalAnnals of Surgical Oncology
Volume25
Issue number4
DOIs
Publication statusPublished - 2018 Apr 1

Fingerprint

Hypopharyngeal Neoplasms
Robotics
Combination Drug Therapy
Clinical Trials
Survival Rate
Laryngeal Neoplasms
Enteral Nutrition
Deglutition
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

@article{c9e160899b394d05a49337840b42b7bb,
title = "A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer",
abstract = "Background: We conducted a prospective clinical trial of combination neoadjuvant chemotherapy, transoral robotic surgery (TORS), and customized adjuvant therapy in patients with locally advanced laryngo-hypopharyngeal cancer. Methods: Between September 2008 and August 2016, 35 patients were enrolled in this clinical trial. Results: Twenty patients had hypopharyngeal cancer and 15 had laryngeal cancer. Twenty-nine patients (82.9{\%}) had T3 disease and six patients (17.1{\%}) had T4 disease, while 12 patients (34.3{\%}) had stage III disease and 23 patients (65.7{\%}) had stage IV disease. The 3-year disease-specific survival rate was 82.4{\%} and the 3-year disease-free survival rate was 69.48{\%}. Decannulation was successful in 31 of 34 patients at an average of 18 days postoperatively. Among all patients, 83{\%} exhibited a favorable subjective swallowing status, while five patients (14.4{\%}) became dependent on feeding tubes. Conclusions: Neoadjuvant chemotherapy combined with TORS and customized adjuvant therapy, based on detailed pathological information, afforded favorable oncological outcomes and preserved organ functionalities in T3–T4 laryngo-hypopharyngeal cancer.",
author = "Park, {Young Min} and Keum, {Ki Chang} and Kim, {Hye Ryun} and ByoungChul Cho and Kim, {Da Hee} and Namhoon Cho and Kim, {Se Heon}",
year = "2018",
month = "4",
day = "1",
doi = "10.1245/s10434-017-6208-5",
language = "English",
volume = "25",
pages = "864--871",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "4",

}

A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer. / Park, Young Min; Keum, Ki Chang; Kim, Hye Ryun; Cho, ByoungChul; Kim, Da Hee; Cho, Namhoon; Kim, Se Heon.

In: Annals of Surgical Oncology, Vol. 25, No. 4, 01.04.2018, p. 864-871.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer

AU - Park, Young Min

AU - Keum, Ki Chang

AU - Kim, Hye Ryun

AU - Cho, ByoungChul

AU - Kim, Da Hee

AU - Cho, Namhoon

AU - Kim, Se Heon

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: We conducted a prospective clinical trial of combination neoadjuvant chemotherapy, transoral robotic surgery (TORS), and customized adjuvant therapy in patients with locally advanced laryngo-hypopharyngeal cancer. Methods: Between September 2008 and August 2016, 35 patients were enrolled in this clinical trial. Results: Twenty patients had hypopharyngeal cancer and 15 had laryngeal cancer. Twenty-nine patients (82.9%) had T3 disease and six patients (17.1%) had T4 disease, while 12 patients (34.3%) had stage III disease and 23 patients (65.7%) had stage IV disease. The 3-year disease-specific survival rate was 82.4% and the 3-year disease-free survival rate was 69.48%. Decannulation was successful in 31 of 34 patients at an average of 18 days postoperatively. Among all patients, 83% exhibited a favorable subjective swallowing status, while five patients (14.4%) became dependent on feeding tubes. Conclusions: Neoadjuvant chemotherapy combined with TORS and customized adjuvant therapy, based on detailed pathological information, afforded favorable oncological outcomes and preserved organ functionalities in T3–T4 laryngo-hypopharyngeal cancer.

AB - Background: We conducted a prospective clinical trial of combination neoadjuvant chemotherapy, transoral robotic surgery (TORS), and customized adjuvant therapy in patients with locally advanced laryngo-hypopharyngeal cancer. Methods: Between September 2008 and August 2016, 35 patients were enrolled in this clinical trial. Results: Twenty patients had hypopharyngeal cancer and 15 had laryngeal cancer. Twenty-nine patients (82.9%) had T3 disease and six patients (17.1%) had T4 disease, while 12 patients (34.3%) had stage III disease and 23 patients (65.7%) had stage IV disease. The 3-year disease-specific survival rate was 82.4% and the 3-year disease-free survival rate was 69.48%. Decannulation was successful in 31 of 34 patients at an average of 18 days postoperatively. Among all patients, 83% exhibited a favorable subjective swallowing status, while five patients (14.4%) became dependent on feeding tubes. Conclusions: Neoadjuvant chemotherapy combined with TORS and customized adjuvant therapy, based on detailed pathological information, afforded favorable oncological outcomes and preserved organ functionalities in T3–T4 laryngo-hypopharyngeal cancer.

UR - http://www.scopus.com/inward/record.url?scp=85032703377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032703377&partnerID=8YFLogxK

U2 - 10.1245/s10434-017-6208-5

DO - 10.1245/s10434-017-6208-5

M3 - Article

C2 - 29086129

AN - SCOPUS:85032703377

VL - 25

SP - 864

EP - 871

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 4

ER -